EORTC Vulva Cancer Module (EORTC VU34)

  • Research type

    Research Study

  • Full title

    An international field study of the reliability and validity of the EORTC Vulva Cancer Module (EORTC VU34)

  • IRAS ID

    236436

  • Contact name

    Andrew Nordin

  • Contact email

    anordin@nhs.net

  • Sponsor organisation

    East Kent Hospitals University NHS Foundation Trust

  • Clinicaltrials.gov Identifier

    00, Not applicable

  • Duration of Study in the UK

    1 years, 9 months, 2 days

  • Research summary

    Carcinoma of the vulva is an uncommon gynaecological malignancy, primarily affecting elderly, menopausal women with an incidence of 2-3/100.000 women. However, the incidence of vulva cancer among younger women has increased over recent decades and today 15-25% of the patients diagnosed with vulva cancer are under the age of 50. The surgical procedures for vulva cancer are mutilating and the morbidity associated to primary surgery to the vulva and the groin and adjuvant (chemo) irradiation is considerable. There are several unresolved treatment related issues that are currently being tested.
    The EORTC vulva cancer module was developed as a disease- and treatment specific questionnaire module for vulva cancer patients to supplement the EORTC QLQ-C30. The purpose with the developmental project was to develop a questionnaire module that allowed broad international cross-cultural and cross-country adaptation and use in clinical trials. The instrument was intended to be a robust instrument with sensitive sub-scales. The first 3 phases of questionnaire development have been completed successfully. The provisional EORTC Vulva Cancer module (VU34) consists of, 10 multi-item scales and 1 single item.
    The aim of this international field study is to test the scale structure, reliability, and validity of the EORTC VU34 in patients diagnosed with vulva cancer, at different stages of disease, and with different treatment modalities. We will investigate the cross-cultural applicability and acceptability in a balanced sample of vulva cancer patients from 10 European countries.

  • REC name

    West Midlands - South Birmingham Research Ethics Committee

  • REC reference

    18/WM/0136

  • Date of REC Opinion

    17 May 2018

  • REC opinion

    Favourable Opinion